Close
  Indian J Med Microbiol
 

Figure 1: A comparison of Len/Dex treatment duration and PFS2 between the study groups. (a) The median Len/Dex treatment duration for patients treated for symptomatic relapse and biological relapse was 139 and 225 days, respectively (P = 0.876). (b) The median PFS2 in the symptomatic relapse group and biological relapse group was 501 and 1289 days, respectively (P = 0.410). Len/Dex: Lenalidomide and dexamethasone, PFS2: Progression-free survival 2.

Figure 1: A comparison of Len/Dex treatment duration and PFS2 between the study groups. (a) The median Len/Dex treatment duration for patients treated for symptomatic relapse and biological relapse was 139 and 225 days, respectively (<i>P</i> = 0.876). (b) The median PFS2 in the symptomatic relapse group and biological relapse group was 501 and 1289 days, respectively (<i>P</i> = 0.410). Len/Dex: Lenalidomide and dexamethasone, PFS2: Progression-free survival 2.